<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651870</url>
  </required_header>
  <id_info>
    <org_study_id>144HT14020</org_study_id>
    <nct_id>NCT02651870</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3 Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan&#xD;
      and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately&#xD;
      Controlled by Candesartan Monotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2015</start_date>
  <completion_date type="Actual">February 29, 2016</completion_date>
  <primary_completion_date type="Actual">February 25, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean change of sitDBP(sitting diastolic blood pressure)</measure>
    <time_frame>From baseline at week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean change of sitDBP</measure>
    <time_frame>From baseline to week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change of sitSBP</measure>
    <time_frame>From baseline to week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control rate: Patient achieving sitSBP &lt; 140mmHg and sitDBP &lt; 90mmHg</measure>
    <time_frame>From baseline to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate: sitSBP reduction ≥ 20mmHg and sitDBP reduction ≥ 10mmHg</measure>
    <time_frame>From baseline to week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Candesartan 16mg + Amlodipine 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 16mg + Amlodipine 5mg, po, q.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan 16mg + Amlodipine 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan 16mg + Amlodipine 10mg, po, q.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan 16mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Candesartan 16mg, po, q.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan 16mg</intervention_name>
    <arm_group_label>Candesartan 16mg</arm_group_label>
    <arm_group_label>Candesartan 16mg + Amlodipine 10mg</arm_group_label>
    <arm_group_label>Candesartan 16mg + Amlodipine 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg</intervention_name>
    <arm_group_label>Candesartan 16mg + Amlodipine 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10mg</intervention_name>
    <arm_group_label>Candesartan 16mg + Amlodipine 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 19 or above&#xD;
&#xD;
          -  Inadequately controlled Essential hypertension at Screening&#xD;
&#xD;
               1. Drug naive or didn't take antihypertensive drug within 2 weeks prior to Visit 1&#xD;
&#xD;
                    -  Mean sitDBP ≥ 95mmHg on target arm&#xD;
&#xD;
               2. Taking antihypertensive drug but not controlled&#xD;
&#xD;
                    -  Mean sitDBP ≥ 90mmHg on target arm&#xD;
&#xD;
          -  Inadequately controlled after 4 weeks of Candesartan 16mg monotherapy&#xD;
&#xD;
               -  Mean sitDBP at Visit 2 ≥ 90mmHg on target arm&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The change of mean sitDBP ≥ 10mmHg or mean sitSBP ≥ 20mmHg on target arm at Visit 1&#xD;
&#xD;
          -  Mean sitDBP ≥ 120mmHg or mean sitSBP ≥ 200mmHg on target arm at Visit 1 and Visit 2&#xD;
&#xD;
          -  Known to suspected Stage 2 Hypertension(aortic coarctation, Primary&#xD;
             hyperaldosteronism, renal artery stenosis, pheochromocytoma)&#xD;
&#xD;
          -  Patient with congestive heart failure(NYHA class III, IV)&#xD;
&#xD;
          -  Patient with unstable angina pectoris, myocardial infarction, Valvular heart disease,&#xD;
             arrhythmia(treatment required) within 3 months&#xD;
&#xD;
          -  History of stroke, cerebral hemorrhage within 6 months&#xD;
&#xD;
          -  Type I Diabetes mellitus, Type II Diabetes mellitus with HbA1c &gt; 8.5%&#xD;
&#xD;
          -  History of severe or malignant retinopathy&#xD;
&#xD;
          -  AST/ALT &gt; UNL*3, Serum creatinine &gt; UNL*1.5, K &gt; 5.5mEq/L&#xD;
&#xD;
          -  Patient with acute or chronic inflammatory(treatment required) status&#xD;
&#xD;
          -  Patient who need to take antihypertensive drug besides Investigational products&#xD;
&#xD;
          -  Patient must be treated with medications prohibited for concomitant use during the&#xD;
             study period&#xD;
&#xD;
          -  History of angioedema related to ACE inhibitor or angiotensin II receptor blockers&#xD;
&#xD;
          -  Hypersensitive to Candesartan/Amlodipine&#xD;
&#xD;
          -  Patient who are dependent on drugs or alcohol within 6 months&#xD;
&#xD;
          -  History of disability to drug ADME, active inflammatory bowel syndrome within&#xD;
             12months, impaired pancreatic function, GI bleeding, obstructions of urinary tract&#xD;
&#xD;
          -  Patients treated with other investigational product within 30 days at first time&#xD;
             taking the investigational product&#xD;
&#xD;
          -  Women with pregnant, breast-feeding&#xD;
&#xD;
          -  History of malignant tumor within 5 years&#xD;
&#xD;
          -  Not eligible to participate for the study at the discretion of investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>August 23, 2020</last_update_submitted>
  <last_update_submitted_qc>August 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Candesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

